Standpoint Research Starts Gilead Sciences (GILD) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Standpoint Research Starts Gilead Sciences (GILD) at Buy

Gilead (GILD) Needs Impactful M&A for the Next Leg of Growth - Piper Jaffray

February 3, 2016 9:11 AM EST

Piper Jaffray analyst, Joshua Schimmer, is hoping to see an impactful acquisition to propel Gilead Sciences (NASDAQ: GILD) into its next leg of growth. However, at 7x next year's eps, the stock may have hit bottom.

GILD reported a very strong 4Q15, bolstered by strong HCV sales in Japan, partially offset by limited VA HCV starts in the quarter. The company guided to flat/slightly down product sales in 2016 and a significant uptick in R&D (+12%-23%) and SG&A (+2%-12%). The company is increasing its dividend... More

Gilead Sciences (GILD) Tops Q4 EPS by 32c

February 2, 2016 4:00 PM EST

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $3.32, $0.32 better than the analyst estimate of $3.00. Revenue for the quarter came in at $8.51 billion versus the consensus estimate of $8.13 billion.

Product Sales

Total product sales for the fourth quarter of 2015 were $8.4 billion compared to $7.2 billion for the fourth quarter of 2014. In the fourth quarter of 2015, product sales in the U.S. were $4.8 billion compared to $5.5 billion in the fourth quarter of 2014. In Europe, product sales were $1.7 billion compared to $1.4 billion in the fourth quarter of 2014. Sales in other international locations increased to $1.9... More